Market News

Intra-Cellular Therapies, Inc. (ITCI) Reaches $18.96 After 9.00% Up Move; Diker Management Has Raised Sothebys (BID) Position By $2.30 Million

The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a huge mover today! The stock increased 6.94% or $1.23 during the last trading session, reaching $18.96. About 297,618 shares traded. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has declined 68.76% since February 14, 2017 and is downtrending. It has underperformed by 85.46% the S&P500.The move comes after 9 months positive chart setup for the $1.04 billion company. It was reported on Feb, 14 by We have $20.67 PT which if reached, will make NASDAQ:ITCI worth $93.15M more.

Diker Management Llc increased Sothebys (BID) stake by 55.56% reported in 2017Q3 SEC filing. Diker Management Llc acquired 50,000 shares as Sothebys (BID)’s stock rose 22.01%. The Diker Management Llc holds 140,000 shares with $6.46M value, up from 90,000 last quarter. Sothebys now has $2.48B valuation. The stock increased 2.15% or $0.995 during the last trading session, reaching $47.255. About 192,796 shares traded. Sotheby's (NYSE:BID) has risen 78.16% since February 14, 2017 and is uptrending. It has outperformed by 61.46% the S&P500.

Investors sentiment increased to 2.77 in 2017 Q3. Its up 1.91, from 0.86 in 2017Q2. It is positive, as 9 investors sold Intra-Cellular Therapies, Inc. shares while 21 reduced holdings. 45 funds opened positions while 38 raised stakes. 39.74 million shares or 30.25% more from 30.51 million shares in 2017Q2 were reported. Blume Management reported 1,000 shares stake. The Hong Kong-based Point72 Asia (Hong Kong) Ltd has invested 0.01% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Panagora Asset Management Incorporated reported 99,024 shares. The New York-based Citigroup has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). C M Bidwell Associates Limited invested in 18,010 shares. Alliancebernstein Lp reported 49,910 shares. Point72 Asset Management Lp stated it has 260,700 shares or 0.02% of all its holdings. Rock Springs Capital Limited Partnership has 187,500 shares. Balyasny Asset Mngmt Ltd Liability Corp invested in 0.01% or 139,353 shares. Acadian Asset Mngmt Limited stated it has 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). State Street Corporation reported 737,763 shares. Rhumbline Advisers holds 0% or 43,676 shares. State Common Retirement Fund has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). First Mercantile Com stated it has 8,791 shares. Atwood & Palmer has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI).

Analysts await Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report earnings on March, 7. They expect $-0.51 earnings per share, up 20.31% or $0.13 from last year’s $-0.64 per share. After $-0.53 actual earnings per share reported by Intra-Cellular Therapies, Inc. for the previous quarter, Wall Street now forecasts -3.77% EPS growth.

Among 11 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. Intra-Cellular Therapies has $104 highest and $1000 lowest target. $54.10’s average target is 185.34% above currents $18.96 stock price. Intra-Cellular Therapies had 36 analyst reports since August 6, 2015 according to SRatingsIntel. JMP Securities upgraded the shares of ITCI in report on Thursday, August 24 to “Market Outperform” rating. The firm earned “Market Perform” rating on Tuesday, May 2 by Leerink Swann. Cowen & Co maintained it with “Buy” rating and $20.0 target in Wednesday, August 23 report. The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) earned “Buy” rating by Cantor Fitzgerald on Wednesday, November 8. The rating was upgraded by SunTrust on Wednesday, November 8 to “Buy”. The firm has “Buy” rating given on Wednesday, August 23 by Cantor Fitzgerald. The firm earned “Neutral” rating on Thursday, September 29 by SunTrust. JMP Securities maintained it with “Market Outperform” rating and $55 target in Wednesday, March 9 report. The stock has “Overweight” rating by Piper Jaffray on Thursday, June 2. Cantor Fitzgerald maintained it with “Buy” rating and $2900 target in Wednesday, August 9 report.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including ParkinsonÂ’s and AlzheimerÂ’s disease. The company has market cap of $1.04 billion. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

Since September 29, 2017, it had 3 buys, and 9 insider sales for $10.92 million activity. Shares for $13,479 were sold by Vanover Kimberly E.. Davis Robert E sold $17,394 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Wednesday, January 3. Another trade for 11,257 shares valued at $192,270 was sold by Mates Sharon. On Monday, October 2 ALAFI MOSHE bought $4.00M worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) or 258,065 shares. LERNER RICHARD A sold $105,630 worth of stock or 7,000 shares. On Monday, October 2 the insider ALAFI CAPITAL CO LLC bought $4.00M. Halstead Michael sold $69,179 worth of stock.

Diker Management Llc decreased Broadsoft Inc (NASDAQ:BSFT) stake by 44,700 shares to 59,300 valued at $2.98M in 2017Q3. It also reduced Live Nation Entertainment In (NYSE:LYV) stake by 40,000 shares and now owns 60,000 shares. Nv5 Global Inc (NASDAQ:NVEE) was reduced too.

Leave a Reply

Your email address will not be published. Required fields are marked *